# Antimicrobial Stewardship in Small Animal Practice: Implementing a Program


## Key Takeaways

- Antimicrobial stewardship in small animal practice is a strategic, multi-faceted approach to responsible antimicrobial use, encompassing more than individual prescription decisions; it involves establishing a dedicated team, developing clinic-specific policies, and implementing structured prescribing protocols.
- A foundational step involves a baseline audit of 30-50 antimicrobial prescriptions to identify current prescribing patterns and target areas for improvement, followed by the creation of concise, one-page guidelines for common clinical scenarios like uncomplicated cystitis or superficial pyoderma.
- Implementing a lower threshold for culture and susceptibility testing is critical, particularly for infections that have failed prior therapy, those requiring fluoroquinolones or third-generation cephalosporins, or in immunocompromised patients, to guide appropriate drug selection and dosage.
- Monitoring program effectiveness requires tracking metrics such as the proportion of consultations resulting in an antimicrobial prescription, the percentage of prescriptions supported by documented infection, and the proportion of critically important antimicrobial classes used, with regular feedback loops for continuous improvement.
- Vaccination protocols should be reviewed as a preventive pillar of stewardship, as vaccines directly reduce the incidence of bacterial diseases, thereby decreasing the overall need for antimicrobial therapy.
- Common failure modes include guideline drift, a "checkbox" approach to documentation without behavioral change, and reliance on a single individual; early detection involves regular audits, monitoring compliance with established protocols, and fostering a culture of collective decision-making.

---

Antimicrobial stewardship is a coherent set of actions that promote using antimicrobials responsibly, a strategy instead of a single intervention or prescription-level decision [Dyar et al., ESGAP definition of antimicrobial stewardship](https://pubmed.ncbi.nlm.nih.gov/28882725/). For the small animal practitioner, a stewardship program translates this strategy into daily clinical workflow: choosing the right drug, at the right dose, for the right duration, and only when bacterial infection is confirmed or strongly suspected. This article provides a step-by-step guide to establishing such a program in a companion animal clinic, from building the foundational team and policy framework to implementing prescribing protocols, measuring outcomes, and sustaining change over time.

The intended reader is the practicing veterinarian who sees canine and feline patients in general practice, emergency medicine, or referral settings. The article answers a practical question: how does a clinic move from individual, case-by-case antimicrobial decisions to a structured, auditable program that improves patient outcomes and reduces selection pressure for resistance? It assumes familiarity with clinical microbiology, pharmacology, and common infectious disease presentations in dogs and cats. Farm animal stewardship, aquaculture, and food production systems are outside the scope, although the scientific rationale for stewardship draws on the same One Health principles that govern those sectors [Schar et al., global trends in antimicrobial use in aquaculture](https://pubmed.ncbi.nlm.nih.gov/33318576/).

The evidence that structured stewardship programs change prescribing behavior is drawn largely from human healthcare. A systematic review and meta-analysis of 52 studies across healthcare and income settings found that targeted antimicrobial stewardship programs were associated with reduced antibiotic consumption, measured as both the proportion of patients receiving a prescription and defined daily doses per 100 patient-days [Zay Ya et al., systematic review of antimicrobial stewardship programs and antibiotic use](https://pubmed.ncbi.nlm.nih.gov/36757700/). Veterinary-specific outcome data are more limited, but the mechanisms of behavior change, audit, and feedback are transferable. The program design in this article adapts those mechanisms to the realities of small animal practice, where caseload is heterogeneous, diagnostic testing is often point-of-care, and client expectations influence prescribing decisions.

## At a Glance

| Parameter | Recommendation | Rationale |
|---|---|---|
| Program lead | Designate one veterinarian as stewardship champion | Accountability and continuity |
| Core team | Champion, one nurse or technician, one practice manager | Workload distribution and administrative support |
| Baseline audit | Retrospective review of 30 to 50 antimicrobial prescriptions | Identifies current prescribing patterns and targets for change |
| Prescribing policy | Written, clinic-specific guidelines for common infections | Reduces variability and supports non-prescribing decisions |
| Diagnostic threshold | Culture and susceptibility testing before starting or continuing therapy for non-responding, recurrent, or severe infections | Confirms bacterial aetiology and guides drug selection |
| Duration review | Scheduled reassessment at 48 to 72 hours for empirical therapy | Allows de-escalation, cessation, or change based on response and culture results |
| Outcome measure | Monthly tracking of defined daily doses per 100 patient visits, or proportion of visits with an antimicrobial prescription | Quantifies program impact over time |
| Education | Quarterly staff sessions on resistance, microbiology, and stewardship updates | Maintains knowledge and engagement |

## What Antimicrobial Stewardship Is and Is Not

The term antimicrobial stewardship has expanded rapidly in use, and with that expansion has come ambiguity. Some descriptions over-emphasize individual prescription choices, while others under-emphasize the societal consequences of antimicrobial use. The ESCMID Study Group for Antimicrobial stewardshiP has argued for viewing stewardship as a strategy, a coherent set of actions that promote responsible antimicrobial use, instead of a checklist applied to single prescriptions [Dyar et al., ESGAP definition of antimicrobial stewardship](https://pubmed.ncbi.nlm.nih.gov/28882725/). This distinction matters for program design. A clinic that simply audits whether amoxicillin-clavulanate was dosed correctly has not implemented stewardship. A clinic that has examined why that drug was chosen, whether it was indicated at all, and what alternatives existed has begun to build a program.

Antimicrobial stewardship is also not synonymous with antibiotic restriction. Restriction is one possible intervention, but stewardship encompasses education, guidelines, rapid diagnostics, vaccination, and infection prevention. Vaccines deserve particular attention because they prevent bacterial disease directly, reducing the need for antimicrobial therapy altogether [Jansen et al., vaccines as a tool to reduce bacterial antimicrobial resistance](https://pubmed.ncbi.nlm.nih.gov/29315295/). A stewardship program in small animal practice should therefore include a vaccination protocol review as a preventive pillar, also a prescribing audit.

## The Resistance Problem in Companion Animals

Multidrug-resistant bacteria are no longer confined to hospital environments or food animal production. They are found in companion animals, and their spread is driven by the same factors that operate in human medicine: excessive use of broad-spectrum agents, incomplete courses, and insufficient stewardship [Vivas et al., multidrug-resistant bacteria and alternative control methods](https://pubmed.ncbi.nlm.nih.gov/30811275/). The estimate that no effective antibiotics will be available by 2050 if new drugs are not developed is frequently cited, but the more immediate clinical problem is already present: resistant infections in dogs and cats that fail first-line therapy, require repeated visits, and limit therapeutic options.

Surveillance systems in human and food animal medicine have demonstrated the value of integrated resistance monitoring. The National Antimicrobial Resistance Monitoring System in the United States has spent two decades tracking resistance in enteric bacteria from humans, retail meat, and food animals, using a One Health approach that links data across species [Karp et al., NARMS integrated surveillance of antimicrobial resistance](https://pubmed.ncbi.nlm.nih.gov/28792800/). Companion animals are not yet included in most national surveillance frameworks, which means individual clinics must generate their own local resistance data through culture and susceptibility testing. This local data is the foundation for clinic-specific prescribing guidelines.

## Why a Program instead of Individual Judgment

Individual clinical judgment is necessary but insufficient as a stewardship mechanism. Prescribing decisions are influenced by diagnostic uncertainty, client pressure, time constraints, and habit. A program creates structure around those decisions: explicit criteria for when antibiotics are indicated, default durations, and a requirement to document the rationale for each prescription. The meta-analytic evidence from human healthcare shows that structured programs, not education alone, change prescribing behavior [Zay Ya et al., systematic review of antimicrobial stewardship programs and antibiotic use](https://pubmed.ncbi.nlm.nih.gov/36757700/). The same logic applies in veterinary practice, where the absence of a program leaves each clinician to reinvent decisions case by case.

## Regulatory and Professional Context

Veterinary stewardship operates within a regulatory framework that varies by jurisdiction. In the United States, the Food and Drug Administration Center for Veterinary Medicine oversees approved animal drugs, labeling, extralabel use, and compounding policy [FDA CVM animal drug information](https://www.fda.gov/animal-veterinary). Professional organizations such as the American Veterinary Medical Association publish guidance on judicious antimicrobial use and stewardship principles for practitioners [AVMA antimicrobial use and stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). Internationally, the World Organization for Animal Health sets terrestrial animal health standards that include antimicrobial resistance surveillance and responsible use provisions [WOAH terrestrial animal health code](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/). A clinic establishing a stewardship program should review the requirements that apply in its own region, because the legal obligations around prescription, dispensing, and record keeping differ between countries and states.

## The Scientific Basis for Stewardship Interventions

The core logic of stewardship rests on the relationship between antimicrobial exposure and resistance selection. Every antimicrobial course applies selective pressure to the bacterial population, favouring resistant clones within the patient and, through excretion, within the wider environment. Reducing unnecessary exposure reduces that pressure. The interventions that achieve this fall into three categories: reducing the number of prescriptions, optimizing drug selection when prescription is warranted, and shortening duration to the minimum effective course. Each category requires different tools. Reducing prescriptions requires diagnostic algorithms and client communication skills. Optimizing selection requires culture and susceptibility data, local resistance patterns, and knowledge of pharmacokinetics and pharmacodynamics. Shortening duration requires evidence for the shortest effective course in each condition, which for many canine and feline infections is still being established.

The evidence base for specific durations in small animal medicine is thinner than in human medicine. Practitioners should therefore consult current formularies and peer-reviewed veterinary references for each condition [MSD Veterinary Manual professional edition](https://www.msdvetmanual.com/), and where evidence is lacking, the program should flag that uncertainty instead of hide it. A stewardship program that acknowledges evidence gaps and builds in a mechanism for updating guidelines as new data emerge is more credible and more durable than one that pretends certainty.

## Building the Program: Governance and Team Structure

A stewardship program succeeds or fails on governance, not on the availability of a formulary. The first practical step is to designate a single accountable lead, typically a senior clinician with an interest in infectious disease, who holds authority to review prescribing patterns and propose changes. This person does not need to be a specialist in veterinary microbiology, but they do need the support of the practice owner or hospital director to enforce policy changes.

The lead should form a small stewardship committee, ideally three to five people, including one nurse or veterinary technician and one representative from the front desk or client communications team. The committee meets monthly. Its standing agenda covers three items: review of audit data, discussion of cases where antimicrobial use deviated from the clinic's guidelines, and updates on resistance patterns from local diagnostic laboratory reports.

Define the committee's scope in writing. The committee should not review every prescription. It should focus on high-impact targets: prophylactic use, empiric therapy for infections where culture is feasible, and use of critically important antimicrobial classes such as fluoroquinolones and third-generation cephalosporins. This targeting matches the evidence that stewardship programs reduce antibiotic consumption most reliably when they focus on specific drugs or conditions instead of attempting to govern all prescribing at once [Zay Ya et al., association between antimicrobial stewardship programs and antibiotic use globally](https://pubmed.ncbi.nlm.nih.gov/36757700/).

## The Baseline Audit: Measuring Current Prescribing

Before changing any behavior, measure it. Conduct a retrospective audit of the preceding 6 to 12 months. Pull every record with an antimicrobial prescription and extract the following fields into a spreadsheet: patient signalment, diagnosis or clinical sign prompting the prescription, drug name, dose, duration, route, whether a culture was submitted, and whether the prescription was dispensed or merely prescribed.

Calculate three baseline metrics. First, the proportion of consultations that resulted in an antimicrobial prescription. Second, the proportion of antimicrobial prescriptions that were supported by a documented bacterial infection, defined as a compatible clinical syndrome with cytologic, culture, or imaging evidence. Third, the proportion of prescriptions for each antimicrobial class, expressed as a percentage of total antimicrobial prescriptions.

Audit at least 100 consecutive cases or all cases over a 3 month period, whichever is larger. If the clinic sees fewer than 100 antimicrobial prescriptions in 3 months, extend the window to 6 months. The goal is a stable denominator, not a rapid result.

Present the baseline data to the whole clinical team. Show the variation between individual clinicians. Variation that cannot be explained by case mix is the strongest argument for adopting shared guidelines. Do not name individual clinicians in the group presentation. Share individual data privately with each clinician.

## Writing Clinic-Specific Guidelines

Generic guidelines from national bodies are a starting point, but they must be adapted to the clinic's case load, laboratory access, and client demographics. The [AVMA antimicrobial use and stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) provide the professional framework, while the [MSD Veterinary Manual](https://www.msdvetmanual.com/) offers species-specific clinical detail for common infections.

Select five to eight common clinical scenarios for the first version of the guidelines. Suitable candidates include uncomplicated urinary tract infection, canine acute diarrhea, feline upper respiratory infection, canine pyoderma, and postoperative prophylaxis for clean-contaminated surgery. For each scenario, the guideline must state four elements: the indication for antimicrobial therapy, the first-line drug choice, the dose range with a note to consult the current formulary for exact dosing, and the duration of therapy with a recheck point.

Write each guideline as a one page flowchart or table. Avoid prose paragraphs. The clinician should be able to find the relevant decision point within 30 seconds of opening the document.

| Clinical Scenario | Antimicrobial Indicated? | First-Line Choice | Duration and Recheck |
|---|---|---|---|
| Uncomplicated cystitis, first episode | Yes, if clinical signs and urinalysis support infection | Amoxicillin or trimethoprim-sulfonamide, pending culture | 5 to 7 days, recheck urinalysis if signs persist beyond 48 hours |
| Acute diarrhea, hemorrhagic or non-hemorrhagic, no fever or systemic signs | No, unless sepsis suspected | None | Supportive care, reassess at 24 to 48 hours |
| Feline upper respiratory infection, mild to moderate | No, unless mucopurulent discharge persists beyond 10 days | Doxycycline if indicated | 7 to 10 days, reassess at day 5 |
| Canine superficial pyoderma, localized | Yes | First-generation cephalosporin | 14 to 21 days, recheck at day 14 |
| Postoperative prophylaxis, clean-contaminated surgery | Yes, perioperative only | Cefazolin or amoxicillin-clavulanate | Single dose preoperatively, stop within 24 hours |

The table is a starting template. Each clinic must adjust it to local resistance data. If the clinic's diagnostic laboratory reports high rates of amoxicillin resistance among Escherichia coli isolates from urine, the first-line choice for cystitis must change accordingly.

## The Diagnostic Sequence: Culture Before Antibiotics

The single most effective intervention in a small animal stewardship program is a lower threshold for culture. Set a clinic rule: any infection that has failed one appropriate course of therapy, any infection requiring a fluoroquinolone or third-generation cephalosporin, and any infection in an immunocompromised patient requires culture and susceptibility testing before the prescription is written.

For urine, cystocentesis is the only acceptable collection method for culture. For skin, collect a punch biopsy or aspirate a pustule instead of swabbing the surface. For respiratory disease, collect a transtracheal wash or bronchoalveolar lavage when bacterial infection is suspected. Each of these techniques requires specific equipment, and the stewardship committee should verify that the clinic stocks the necessary supplies and that all clinicians are competent in the collection methods.

When culture results return, the clinician must document the interpretation in the medical record. Record the organizm, the susceptibility profile, and the drug selected. If the clinician chooses a drug that the susceptibility report indicates is resistant, the record must state the clinical justification, such as tissue penetration concerns or a documented adverse reaction to the susceptible drug.

## Monitoring and Feedback Loops

The program's ongoing function depends on a repeating cycle of audit, feedback, and guideline revision. Run the same audit every 6 months. Compare the new data against the baseline. Track three outcomes: the proportion of consultations resulting in an antimicrobial prescription, the proportion of prescriptions supported by documented infection, and the proportion of prescriptions for critically important classes.

Present the results to the team in a 15 minute meeting. Show the trend line, also the latest number. If a metric has not improved, discuss why. Common failure modes include guidelines that are too complex to follow in a busy consultation, clinicians who forget the guidelines exist, and client pressure that overrides clinical judgment. Each failure mode has a different remedy: simplify the guideline, place a summary card at every examination room computer, or provide the team with standard client communication scripts.

The committee should also track adverse outcomes. Record any case where a patient deteriorated after a stewardship decision to withhold or delay antimicrobial therapy. These cases are inevitable and do not necessarily indicate a wrong decision, but they must be reviewed openly. A single negative outcome should not reverse a guideline that is otherwise supported by the evidence. The distinction between a bad outcome and a bad decision is the core judgment of the stewardship committee.

Vaccination is a complementary intervention that reduces the need for antimicrobial therapy by preventing bacterial infections altogether. The [role of vaccines in preventing bacterial antimicrobial resistance](https://pubmed.ncbi.nlm.nih.gov/29315295/) is well documented, and the stewardship program should include a review of the clinic's vaccination protocols to ensure that core vaccines are offered consistently.

## Recognized Failure Modes and Early Detection

Stewardship programs fail in predictable patterns. The most common is guideline drift, where clinicians gradually return to familiar prescribing habits despite agreed protocols. Detect this by repeating the baseline audit at six-month intervals and comparing prescription patterns against the clinic guideline. A second failure mode is the checkbox program, where documentation improves but prescribing behavior does not change. The discriminating check is whether the proportion of first-line agents prescribed, the duration of therapy, and the culture submission rate have actually shifted, not whether forms are complete.

Another frequent failure is the bottleneck effect, where one enthusiastic individual carries the entire program. When that person is absent, compliance collapses. Early detection comes from monitoring whether decisions are made collectively in rounds or journal clubs, or whether they depend on a single clinician's availability. A related problem is guideline rigidity, where protocols are applied without allowance for legitimate clinical variation. This produces silent non-compliance, as clinicians bypass the guideline instead of seek an exception. The corrective action is to build a formal exception pathway into the guideline, requiring documented justification and review, so that deviations become data instead of hidden behavior.

## Common Errors in Prescribing Decisions

Less experienced clinicians typically default to broad-spectrum coverage when a narrow agent would suffice. The corrective action is to require a documented answer to the question: what specific pathogen is being treated, and what is the narrowest agent with activity against it? A second recurring error is treating contamination as infection. This is most common with urine samples obtained by cystocentesis that are mishandled, or with skin cultures where surface flora dominate. The corrective action is to establish a laboratory submission protocol that specifies sample type, collection method, and interpretation criteria before results return.

Duration errors are equally common. Clinicians tend to extend therapy to a round number of days instead of to a defined clinical endpoint. The corrective action is to write a stop date or a recheck criterion into every prescription. A fourth error is the reflexive use of prophylactic antibiotics for clean surgical procedures. The corrective action is to embed the clinic's surgical prophylaxis protocol into the anesthesia record so that antibiotic administration requires a specific indication to be ticked.

## Limitations of the Evidence and Areas of Expert Disagreement

The evidence base for veterinary stewardship is thinner than in human medicine. Most intervention studies come from human healthcare, and their findings transfer imperfectly to small animal practice. The systematic review by Zay Ya and colleagues, which pooled 52 studies across healthcare settings, reported that stewardship programs were associated with reduced antibiotic consumption, but the studies were predominantly human and hospital based. Whether the same effect sizes apply in outpatient companion animal practice remains uncertain.

Expert opinion diverges on several practical points. One is the role of topical therapy. Some specialists argue that topical antimicrobials should be the first line for superficial pyoderma and otitis, reserving systemic agents for refractory cases. Others contend that systemic therapy is more reliable in busy practice settings where owner compliance with topical regimens is poor. A second area of disagreement is the threshold for culture. Some authorities recommend culture for any infection that has failed one appropriate course of therapy. Others argue that two failed courses are a more cost-effective threshold, given the expense and turnaround time of culture and susceptibility testing. A third contested area is the use of metronidazole for acute diarrhea. The evidence for benefit is weak, yet the drug remains widely prescribed. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific guidance on these conditions, but it does not resolve the underlying evidence gaps.

## When to Refer, Consult, or Report

Referral or specialist consultation is warranted when a patient has a multidrug-resistant infection that has failed appropriate first-line and second-line therapy, when an infection involves a site where surgical source control is required, or when the clinician is uncertain whether infection is present at all. Laboratory involvement should be escalated when culture results are discordant with clinical response, when unusual organizms are isolated, or when susceptibility testing suggests resistance patterns that do not match the clinic's local epidemiology.

Regulatory reporting obligations vary by jurisdiction. Clinicians should know which organizms are notifiable in their region and how to report them. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) provides regulatory information on approved drugs and adverse event reporting, while the [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) describe international surveillance expectations. When a treatment failure involves a drug used in an extralabel manner, the clinician should document the basis for that decision and report any suspected adverse reaction through the appropriate national system.

## Troubleshooting Table

| Observation | Likely Cause | Discriminating Check |
| --- | --- | --- |
| Prescribing patterns unchanged after guideline introduction | Guideline not integrated into workflow | Compare audit data before and after, check whether guideline is accessible at point of prescribing |
| Culture submission rates low despite protocol | Cost or turnaround time barriers | Survey clinicians on barriers, review laboratory invoice data |
| Compliance high on paper, poor in practice | Documentation completed retrospectively | Compare chart times against appointment times, spot-check records |
| One clinician's cases show consistently different prescribing | Individual resistance to protocol | Review that clinician's cases in morbidity and mortality rounds |
| Guidelines applied without exceptions | Fear of criticism for deviation | Check whether exception pathway is used, review culture of team meetings |
| Repeated isolation of multidrug-resistant organizms | Inadequate infection control, not prescribing failure | Review hospital hygiene protocols and environmental sampling |

## Frequently Asked Questions

### How Much Does an Antimicrobial Stewardship Program Cost, and How Can a Small Clinic Afford One?

The largest cost is staff time, not software or laboratory fees. A practical program can begin with a single monthly meeting and a simple spreadsheet audit of prescriptions. Culture and susceptibility testing adds direct cost per case, but targeted therapy often reduces overall expense by shortening treatment duration and avoiding drug reactions. Clinics with limited budgets can prioritize one common infection type, such as urinary tract disease, and build guidelines around that condition first. Free resources from professional bodies, including the [AVMA antimicrobial use and stewardship guidance](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance), provide templates and frameworks that reduce development time. The [systematic review and meta-analysis of stewardship programs](https://pubmed.ncbi.nlm.nih.gov/36757700/) shows that structured interventions reduce antibiotic consumption across health care settings, which supports the argument that even modest programs yield measurable returns.

### What Should We Do When Culture and Susceptibility Testing Is Not Available or the Owner Declines It?

Empirical therapy remains acceptable when sampling is impossible, provided the clinician documents the reasoning and selects the narrowest agent likely to be effective. If the owner declines culture, explain that the result directly determines whether the current drug is correct, whether the dose can be reduced, and how long treatment must continue. Offer a compromise: start empirical therapy, collect the sample at the first revisit, and adjust once results return. For recurrent infections, culture becomes more important because resistance probability rises with each prior exposure. When laboratory access is genuinely unavailable, consult the [MSD Veterinary Manual](https://www.msdvetmanual.com/) for species-specific empirical choices and review the clinic formulary to identify narrow-spectrum options. Record the refusal and the clinical rationale in the medical record.

### How Should We Document Stewardship Decisions in the Medical Record?

Record the suspected infection site, the clinical severity, the drug selected, the dose, the planned duration, and the review date. If culture was not performed, state why. If the drug choice deviates from the clinic guideline, document the specific patient factor that justified the deviation. This record supports continuity when another clinician sees the case and provides the data needed for future audits. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) maintains drug-specific labeling information that should be referenced when documenting extralabel use. A standardized template or checklist embedded in the practice information management system reduces documentation time and improves completeness. Review a sample of records at each stewardship meeting to identify patterns, such as repeated failure to record a stop date.

### How Do I Explain a Stewardship Decision to a Client Who Expects Antibiotics?

Frame the conversation around the specific diagnosis and the expected benefit, not around antibiotic policy. State clearly that the infection may be viral or self-limiting, that antibiotics carry risks such as vomiting or resistant infections, and that the chosen plan is the safest effective option. For bacterial infections, explain that culture identifies the drug most likely to work the first time. For conditions where antibiotics are not indicated, offer a concrete alternative such as a recheck examination, symptomatic treatment, or a diagnostic test. The [role of vaccines in preventing bacterial antimicrobial resistance](https://pubmed.ncbi.nlm.nih.gov/29315295/) provides a useful analogy: prevention reduces the need for treatment. Clients respond well to a written aftercare plan that includes the reason antibiotics were or were not prescribed and the signs that should prompt a return visit.

### What Metrics Should We Track to Show the Program Is Working?

Track the proportion of antimicrobial prescriptions supported by culture, the percentage of prescriptions with a recorded stop date, and total antimicrobial courses per 100 patient visits. For common conditions such as uncomplicated cystitis, track guideline adherence specifically. Review aggregate data quarterly instead of monthly to avoid overreacting to normal variation. The [National Antimicrobial Resistance Monitoring System](https://pubmed.ncbi.nlm.nih.gov/28792800/) demonstrates how integrated surveillance over time reveals trends that single-case review cannot. Compare your clinic's culture positivity rates and resistance patterns with regional data if available. Share the results with the whole team, including veterinary nurses and reception staff, because their observations about case flow and owner concerns often explain prescribing patterns that clinicians miss.

### How Does Stewardship Differ for Exotic Pets, Birds, or Wildlife Patients?

The same principles apply, but the evidence base is thinner and the practical constraints are different. Many exotic species have no approved antimicrobial products, so extralabel use is routine and must be documented carefully. Dosing is often extrapolated from other species, which increases the value of culture and susceptibility testing. Sample collection may require anesthesia, so plan diagnostics to coincide with other procedures. For wildlife, treatment duration may be limited by release timelines, and the [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) provide context on disease control obligations. Consult a specialist or referral laboratory when treating less common species, and report unusual resistance patterns to the relevant surveillance program. The clinic guideline should include a section on exotics that names the reference sources the practice accepts as authoritative.

## Related Clinical & Scientific Guides

* [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
* [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary)
* [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive)


## References and Further Reading

- [What is antimicrobial stewardship?](https://pubmed.ncbi.nlm.nih.gov/28882725/). 2017.
- [Association Between Antimicrobial Stewardship Programs and Antibiotic Use Globally: A Systematic Review and Meta-Analysis.](https://pubmed.ncbi.nlm.nih.gov/36757700/). 2023.
- [The role of vaccines in preventing bacterial antimicrobial resistance.](https://pubmed.ncbi.nlm.nih.gov/29315295/). 2018.
- [Multidrug-Resistant Bacteria and Alternative Methods to Control Them: An Overview.](https://pubmed.ncbi.nlm.nih.gov/30811275/). 2019.
- [Global trends in antimicrobial use in aquaculture.](https://pubmed.ncbi.nlm.nih.gov/33318576/). 2020.
- [National Antimicrobial Resistance Monitoring System: Two Decades of Advancing Public Health Through Integrated Surveillance of Antimicrobial Resistance.](https://pubmed.ncbi.nlm.nih.gov/28792800/). 2017.
- [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM.
- [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.

## Related Articles

- [Antimicrobial Stewardship in Equine Practice: Challenges and Solutions](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-equine-practice-challenges-solutions)
- [Antimicrobial Stewardship in Food Animals: Principles and Practical Application](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-food-animals-principles-practical-application)
- [Antimicrobial Stewardship in Food Animals: Withdrawal Times and Residue Avoidance](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-food-animals-withdrawal-times-residue-avoidance)
- [Antimicrobial Stewardship in Respiratory Infections of Dogs and Cats](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-respiratory-infections-dogs-cats)
- [Antimicrobial Stewardship in Canine Diarrhea: When Antibiotics Are Not the Answer](/knowledge/veterinary-medicine/clinical-pharmacology/antimicrobial-stewardship-canine-diarrhea)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.